EntryPoint Capital’s Denali Therapeutics DNLI Stock Holding History

EntryPoint Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,058	Closed	-$349K	–	706
2025 Q3	$349K	Buy	+24,058	New	+$346K	0.14%	304

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EntryPoint Capital's DNLI Position: Q4 2025 in Review

EntryPoint Capital sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 24,058 shares — an estimated $349K sold.

EntryPoint Capital first reported a position in DNLI in Q3 2025 and held it in 1 quarter. The position peaked at $349K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

EntryPoint Capital reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 24,058 Denali Therapeutics shares in Q4 2025, an estimated $349K.
EntryPoint Capital first reported a position in Denali Therapeutics in Q3 2025 and held it in 1 quarter.
EntryPoint Capital's Denali Therapeutics position peaked at $349K in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.